We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

54 hedge funds and large institutions have $40.2M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

9% less capital invested

Capital invested by funds: $44.4M → $40.2M (-$4.13M)

14% less funds holding

Funds holding: 63 → 54 (-9)

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
54
Holders Change
-9
Holders Change %
-14.29%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
17
Reduced
15
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NC
Nexthera Capital
New York
+$1.52M
2
ECM
Endurant Capital Management
California
+$525K
3
BC
Broadfin Capital
New York
+$479K
4
Primecap Management
Primecap Management
California
+$323K
5
EIM
Essex Investment Management
Massachusetts
+$231K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.23M
2
Ameriprise
Ameriprise
Minnesota
-$654K
3
First Eagle Investment Management
First Eagle Investment Management
New York
-$507K
4
CM
Crestline Management
Texas
-$483K
5
DGI
Disciplined Growth Investors
Minnesota
-$351K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$126K -$46 -19 -0%
AIM
27
Alambic Investment Management
California
$114K -$134K -55,913 -51%
PCM
28
Prelude Capital Management
New York
$114K +$129K +53,964 New
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$110K +$90.1K +37,608 +266%
Macquarie Group
30
Macquarie Group
Australia
$109K -$69.8K -29,127 -36%
Millennium Management
31
Millennium Management
New York
$105K +$119K +49,557 New
NSEDCP
32
NJ State Employees Deferred Compensation Plan
New Jersey
$81K – – –
Tudor Investment Corp
33
Tudor Investment Corp
Connecticut
$68K – – –
State Street
34
State Street
Massachusetts
$67K +$4.2K +1,752 +6%
KAM
35
Kazazian Asset Management
Florida
$67K +$26.3K +10,972 +54%
Wells Fargo
36
Wells Fargo
California
$61K -$1.81K -755 -3%
PAM
37
Panagora Asset Management
Massachusetts
$54K -$12.2K -5,104 -17%
Goldman Sachs
38
Goldman Sachs
New York
$51K +$28.3K +11,801 +95%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$50K -$2 -1 -0%
Two Sigma Investments
40
Two Sigma Investments
New York
$49K -$11.9K -4,956 -18%
Two Sigma Advisers
41
Two Sigma Advisers
New York
$44K -$3.35K -1,400 -6%
Citadel Advisors
42
Citadel Advisors
Florida
$40K -$1.59K -664 -3%
TRCT
43
Tower Research Capital (TRC)
New York
$36K +$28.1K +11,734 +222%
HCM
44
Hodges Capital Management
Texas
$33K – – –
Morgan Stanley
45
Morgan Stanley
New York
$28K +$1.41K +590 +5%
Baird Financial Group
46
Baird Financial Group
Wisconsin
$25K – – –
Simplex Trading
47
Simplex Trading
Illinois
$8K -$39.2K -16,354 -81%
MAM
48
Meeder Asset Management
Ohio
$7K +$3.74K +1,563 +103%
UBS Group
49
UBS Group
Switzerland
$3K -$2.79K -1,164 -49%
Fidelity Investments
50
Fidelity Investments
Massachusetts
$2K +$1.99K +831 New
1
2
3

OMED Hedge Fund Activity: Q3 2018 in Review

54 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2018, worth a combined $40.2M — down 9.3% from $44.4M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of OMED and 8 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 17 added.

The largest buyer was Nexthera Capital, opening a new position worth an estimated $1.52M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.23M sold.

  • 54 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2018, down from 63 in Q2 2018.
  • Funds reported $40.2M of OncoMed Pharmaceuticals, Inc. stock for Q3 2018, down 9.3% quarter-over-quarter.
  • 8 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2018 and 17 closed out, a net change of -9 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2018 was Nexthera Capital, an estimated $1.52M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2018 was Alyeska Investment Group, an estimated $1.23M sold.

Based on aggregated 13F filings for Q3 2018.